Have a feature idea you'd love to see implemented?
Let us know!
SRPT Sarepta Therapeutics Inc
Price (delayed)
$129.52
Market cap
$12.35B
P/E Ratio
172.69
Dividend/share
N/A
EPS
$0.75
Enterprise value
$13.34B
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going
Highlights
The net income has soared by 180% QoQ and by 105% YoY
The EPS has soared by 107% YoY and by 83% from the previous quarter
Sarepta Therapeutics's quick ratio has decreased by 37% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of SRPT
Market
Valuations
Earnings
Shares outstanding
95.37M
Market cap
$12.35B
Enterprise value
$13.34B
Price to earnings (P/E)
172.69
Price to book (P/B)
11.37
Price to sales (P/S)
8.14
EV/EBIT
214.36
EV/EBITDA
113.39
EV/Sales
8.86
Revenue
$1.5B
EBIT
$62.22M
EBITDA
$117.63M
Free cash flow
-$506.82M
Per share
Balance sheet
Liquidity
EPS
$0.75
Free cash flow per share
-$5.36
Book value per share
$11.39
Revenue per share
$15.91
TBVPS
$36.19
Total assets
$3.42B
Total liabilities
$2.35B
Debt
$1.37B
Equity
$1.08B
Working capital
$2B
Debt to equity
1.27
Current ratio
3.9
Quick ratio
2.64
Net debt/EBITDA
8.38
Margins
Efficiency
Dividend
EBITDA margin
7.8%
Gross margin
88.3%
Net margin
3.1%
Operating margin
2.5%
Return on assets
1.5%
Return on equity
5.2%
Return on invested capital
1.7%
Return on capital employed
2.3%
Return on sales
4.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SRPT stock price
How has the Sarepta Therapeutics stock price performed over time
Intraday
-0.53%
1 week
-0.28%
1 month
3.71%
1 year
20.32%
YTD
34.32%
QTD
3.71%
Financial performance
How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$1.5B
Gross profit
$1.33B
Operating income
$37.99M
Net income
$47.3M
Gross margin
88.3%
Net margin
3.1%
The net income has soared by 180% QoQ and by 105% YoY
SRPT's net margin has surged by 158% since the previous quarter and by 103% year-on-year
SRPT's operating income has soared by 140% since the previous quarter and by 107% year-on-year
SRPT's operating margin has soared by 137% from the previous quarter and by 105% YoY
Growth
What is Sarepta Therapeutics's growth rate over time
Valuation
What is Sarepta Therapeutics stock price valuation
P/E
172.69
P/B
11.37
P/S
8.14
EV/EBIT
214.36
EV/EBITDA
113.39
EV/Sales
8.86
The EPS has soared by 107% YoY and by 83% from the previous quarter
The company's equity rose by 45% YoY and by 12% QoQ
SRPT's P/B is 17% below its 5-year quarterly average of 13.7 and 12% below its last 4 quarters average of 13.0
The revenue rose by 50% YoY and by 7% QoQ
The P/S is 40% less than the 5-year quarterly average of 13.6 and 8% less than the last 4 quarters average of 8.9
Efficiency
How efficient is Sarepta Therapeutics business performance
The ROA has soared by 200% from the previous quarter and by 105% YoY
The return on equity has surged by 160% since the previous quarter and by 103% year-on-year
Sarepta Therapeutics's ROIC has soared by 106% YoY and by 70% from the previous quarter
The ROS has soared by 105% YoY and by 71% from the previous quarter
Dividends
What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SRPT.
Financial health
How did Sarepta Therapeutics financials performed over time
The total assets is 46% more than the total liabilities
Sarepta Therapeutics's quick ratio has decreased by 37% YoY and by 9% from the previous quarter
The company's current ratio fell by 21% YoY and by 3.7% QoQ
SRPT's debt is 27% greater than its equity
The company's equity rose by 45% YoY and by 12% QoQ
The debt to equity has declined by 31% year-on-year and by 12% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.